Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 9/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655828 | 1.00 | GRIA4 (0.41) | GRIA4GRIA2ALDH1A1MAPTNPSR1 | |
| SCHEMBL2660518 | 0.91 | PPARD (0.39) | DAO | |
| SCHEMBL2655358 | 0.91 | PPARD (0.39) | DAO | |
| SCHEMBL2655543 | 0.88 | GRIA4 (0.40) | GRIA4GRIA2ALDH1A1MAPTNPSR1 | |
| SCHEMBL2655718 | 0.87 | MAPT (0.38) | GRIA4ALDH1A1MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL2655722 | 0.87 | MAPT (0.38) | GRIA4ALDH1A1MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL2660674 | 0.85 | GCGR (0.46) | KMT2A | |
| SCHEMBL2660676 | 0.85 | GCGR (0.46) | KMT2A | |
| SCHEMBL2655639 | 0.85 | PPARD (0.41) | GRIA4GRIA2ALDH1A1MAPTNPSR1 | |
| SCHEMBL2655576 | 0.84 | PPARD (0.39) | GRIA4GRIA2ALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807702-B2 | Substituted thiophene carboxylic amide glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-10-05 | — | — | US | claimed |
| EP-1957484-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-03-03 | — | — | EP | claimed |
| US-20080300289-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | claimed |
| EP-1957484-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007120284-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | WO | claimed |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| US-7807702-B2 | Substituted thiophene carboxylic amide glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1957484-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20080300289-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | disclosed |
| EP-1957484-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007120284-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300289-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | GRIA4 641/4885GRIA2 426/4885ALDH1A1 3337/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | GRIA4 1227/4885GRIA2 991/4885ALDH1A1 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.